NVS - IPO Update: Poseida Therapeutics Proposes $150 Million IPO
Quick Take
Poseida Therapeutics (PSTX) intends to raise $150 million in an IPO of its common stock, according to an amended registration statement.
The company is advancing immuno-oncology and genetic-based treatments for various cancer indications.
PSTX is still at a very early stage of development with an ultra high risk profile, the IPO valuation is quite high and there is no investor support for the IPO, so my opinion is NEUTRAL.
Company & Technology
San Diego, California-based Poseida was founded to develop CAR-T and Cas-CLOVER genetic therapy approaches to treating blood cancers